Merck Signs Wide-Ranging MOU To Help Beef Up Korea's Global R&D Capabilities
This article was originally published in PharmAsia News
SEOUL - Merck & Co. Inc. has signed a memorandum of understanding with South Korea to invest KRW 210 billion ($192.9 million) in the country for research and development of new drugs, including manpower exchanges, Korea's Ministry of Health and Welfare said
You may also be interested in...
Marking the conclusion of a 2009 MOU, Sanofi signed a letter of intent with the Korean government to take R&D investments to a new level.
Tax credits, priority for government projects and expanded funding opportunities will support 42 Korean firms and Korea-heavy Otsuka Pharmaceutical with R&D expansion
After winning regulatory approval Dec. 29, Pfizer launches Xalkori in Korea, leveraging a clinical program that has included a significant percentage of Korean patients.